Development Of Effective Biomarkers For The Diagnosis And Prognosis Of Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,062,585.00
Summary
Every year ~20,000 Australian men are diagnosed with prostate cancer and more than 3,000 die of this disease. The current PSA test for the diagnosis of prostate cancer is not specific and this can result in incorrect diagnosis, unnecessary biopsies and lead to wrong treatments. We have discovered a novel change in the biology of prostate cancer. We will use this information to develop new tests for prostate cancer, which provide early accurate detection and can predict disease progression.
Quantitative Proteomic Analysis Of Faecal Biomarkers For Colon Cancer
Funder
National Health and Medical Research Council
Funding Amount
$562,398.00
Summary
We have identified a number of potential biomarkers present in the stools of patients with colorectal cancer (CRC). We will use quantitative mass spectrometric techniques that we have developed to validate these biomarkers on a large number of faecal samples from patients with CRC and multiple control groups. We believe these studies will lead to a new panel of biomarkers which will improve the detection of early forms of colon cancer, thus reducing death from this disease.
Prognostic Importance Of Androgen Receptors In Epithelium And Stroma In Early Stage Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$348,750.00
Summary
The use of serum prostate specific antigen (PSA) to screen asymptomatic men for prostate cancer has reduced the stage of disease at diagnosis. The majority of tumours are now small and potentially organ-confined. The use of nomograms, algorithms based on preoperative clinical features of these patients (serum PSA level, Gleason grade, clinical stage) has facilitated this process, but is imperfect as 20-30% of patients experience disease relapse within 5-7 years. Tumours with similar preoperative ....The use of serum prostate specific antigen (PSA) to screen asymptomatic men for prostate cancer has reduced the stage of disease at diagnosis. The majority of tumours are now small and potentially organ-confined. The use of nomograms, algorithms based on preoperative clinical features of these patients (serum PSA level, Gleason grade, clinical stage) has facilitated this process, but is imperfect as 20-30% of patients experience disease relapse within 5-7 years. Tumours with similar preoperative clinical features have markedly different outcomes, reinforcing the inadequacy of current approaches to determining whether or not an individual patient has organ-confined disease. A new approach is to incorporate into the standard diagnostic nomograms, biological features from preoperative core biopsy linked to the process of disease relapse, and which independently predict patient outcome risk group. Our preliminary studies using a small hypothesis-generating cohort of patients with early stage prostate cancer determined that elevated levels of androgen receptors (AR) in malignant epithelial cells and reduced levels of AR in peritumoral stromal cells independently predict disease relapse after surgery. In this project, AR measurements will be analysed in independent cohorts of patients derived from two Australian institutions to determine whether the predictive value is maintained across multi-Institutional cohorts. Selected androgen-regulated markers of tumour growth and spread (proliferative, apoptotic, metastatic) will be examined in microarrayed postoperative tissue samples. The postoperative markers will be examined for independence of prediction of relapse. Independent markers will be examined for ability to increase predictive efficacy in standard diagnostic nomograms. Levels of the two markers with greatest predictive value will be measured in preoperative core biopsies and tested for predictive ability as a prelude to clinical practice.Read moreRead less
Enabling Personalised Risk Assessment For Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$431,000.00
Summary
Bowel cancer screening will be most effective in disease prevention if it is applied proportionately to individual person's risk. Risk-based screening requires a risk calculator to assess personal risk. By utilising existing large, international datasets, I will identify the risk factors specific for different bowel cancer types and incorporate them to upgrade the prediction model that I have developed. This will achieve more accurate risk prediction to enable personalised risk-based screening.
Skin cancers, including melanoma, present a significant health, social and economic burden in Australia. Despite the rising incidence of melanoma, the most deadly form of skin cancer, there is currently no national or population-based screening program available. The aim of this CRE is to identify how novel skin imaging technologies can be integrated into the pathway to improve early detection, and ultimately reduce the health and economic burden caused by melanoma skin cancer.
Randomized Controlled Trial Of A Video-delivered Intervention For The Early Detection Of Melanoma In Men 50+ Years
Funder
National Health and Medical Research Council
Funding Amount
$511,694.00
Summary
Unfortunately, men over 50 years are most at risk to die from melanoma. Skin self-examination, where a man inspects the skin of his whole body with the help of a mirror or another person, and rapid presentation to a doctor without delay if he detects a suspicious lesion has the potential to increase awareness for the skin and to improve early diagnosis. We want to assess if we can increase the rate of skin self-examination in men 50 years and over through a video-delivered intervention.
Crossover Trial Of Dermoscopy And Short-term Digital Monitoring For The Management Of Skin Lesions In General Practice
Funder
National Health and Medical Research Council
Funding Amount
$192,000.00
Summary
Australia has the highest incidence of melanoma in the world. Early detection of melanoma is critical in reducing the death rate from melanoma. Currently the diagnostic accuracy of melanoma in general practice is poor with around 30 benign lesions being cut out for every one melanoma. This severely impacts on the total health budget, with a cost of $46M per annum in general practice. An improved diagnostic method for detecting melanoma of the skin will allow earlier detection of melanoma and dec ....Australia has the highest incidence of melanoma in the world. Early detection of melanoma is critical in reducing the death rate from melanoma. Currently the diagnostic accuracy of melanoma in general practice is poor with around 30 benign lesions being cut out for every one melanoma. This severely impacts on the total health budget, with a cost of $46M per annum in general practice. An improved diagnostic method for detecting melanoma of the skin will allow earlier detection of melanoma and decrease the rate of needless excision biopsies.Read moreRead less
Circulating Tumour DNA (ctDNA) As A Diagnostic Tool In Colorectal Cancer: Role In Screening And Early Detection Of Metastatic Or Recurrent Disease
Funder
National Health and Medical Research Council
Funding Amount
$500,478.00
Summary
These studies will be exploring the value of using a blood test to detect cancer DNA as a screening test for colorectal cancer. This test promises to be superior to faecal blood testing, which is currently performed as part of the National Bowel Cancer Screening Program. It may also have advantages over colonoscopy as a screening tool. Given the likely acceptability of having a blood based screening test, it is expected that participation rates in bowel cancer screening, which has been shown to ....These studies will be exploring the value of using a blood test to detect cancer DNA as a screening test for colorectal cancer. This test promises to be superior to faecal blood testing, which is currently performed as part of the National Bowel Cancer Screening Program. It may also have advantages over colonoscopy as a screening tool. Given the likely acceptability of having a blood based screening test, it is expected that participation rates in bowel cancer screening, which has been shown to save lives, will be greatly increased.Read moreRead less
Reducing Colorectal Cancer Burden In Young Adults: Precision Prevention And Early Detection
Funder
National Health and Medical Research Council
Funding Amount
$1,449,800.00
Summary
Bowel cancer rate in young adults before age 50 is increasing worldwide including Australia. Since it is impossible to screen everyone, it is critical to identify who is likely to develop the disease, to optimise screening. Using the world's largest resource for young-onset bowel cancer, I will conduct studies to generate high-quality evidence to inform how to best prevent bowel cancer in young adults and translate into the policy and practice, to reduce colorectal cancer burden in young adults.